Stereotactic body radiotherapy for synchronous early stage non-small cell lung cancer

References

• Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225–2249.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076.
   PubMed Web of Science ®Google Scholar
• Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(5):295–301.
   PubMed Web of Science ®Google Scholar
• Videtic GMM, Hu C, Singh AK, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage i peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015;93(4):757–764.
   PubMed Web of Science ®Google Scholar
• Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019;37(15):1316–1325.
   PubMed Web of Science ®Google Scholar
• Ferguson MK. Synchronous primary lung cancers. Chest. 1993;103(4 Suppl):398S–400s.
   PubMed Web of Science ®Google Scholar
• Rosengart TK, Martini N, Ghosn P, et al. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg. 1991;52(4):773–778. discussion 8-9.
   PubMed Web of Science ®Google Scholar
• Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70(4):606–612.
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998;21(2):105–113.
   PubMed Web of Science ®Google Scholar
• Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–59.
   PubMed Web of Science ®Google Scholar
• Chang JY, Liu YH, Zhu Z, et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013;119(18):3402–3410.
   PubMed Web of Science ®Google Scholar
• Rahn DA, 3rd, Thakur S, Makani S, et al. Stereotactic body radiation therapy (SBRT) for multiple primary lung cancers (MPLC): a review and case series. J Radiosurg Sbrt. 2013;2(2):135–140.
   PubMedGoogle Scholar
• Creach KM, Bradley JD, Mahasittiwat P, et al. Stereotactic body radiation therapy in the treatment of multiple primary lung cancers. Radiother Oncol. 2012;104(1):19–22.
   PubMed Web of Science ®Google Scholar
• Nikitas J, DeWees T, Rehman S, et al. Stereotactic body radiotherapy for early-stage multiple primary lung cancers. Clin Lung Cancer. 2019;20(2):107–116.
   PubMed Web of Science ®Google Scholar
• Ayoub Z, Ning MS, Brooks ED, et al. Definitive management of presumed synchronous early stage non-small cell lung cancers: outcomes and utility of stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2020;107(2):261–269.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Lucas JT, Jr., Kuremsky JG, Soike M, et al. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC). Lung Cancer. 2014;85(1):59–65.
   PubMed Web of Science ®Google Scholar
• Petty WJ, Urbanic JJ, Ahmed T, et al. Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;102(3):527–535.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191–192.
   PubMed Web of Science ®Google Scholar
• Shintani T, Masago K, Takayama K, et al. Stereotactic body radiotherapy for synchronous primary lung cancer: clinical outcome of 18 cases. Clin Lung Cancer. 2015;16(5):e91–e96.
   PubMed Web of Science ®Google Scholar
• Verstegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011;101(2):250–254.
   PubMed Web of Science ®Google Scholar
• Berman AT, Jabbour SK, Vachani A, et al. Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. Transl Lung Cancer Res. 2019;8(1):5–14.
   PubMed Web of Science ®Google Scholar
• Gkogkozotou V-KI, Gkiozos IC, Charpidou AG, et al. PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness. Lung Cancer Manag. 2018;7(2):LMT02
   PubMed Web of Science ®Google Scholar
• Lin J, Fernandez F. Indications for invasive mediastinal staging for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018;156(6):2319–2324.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Hu C, Michalski J, et al. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. ASTRO Abstract. 2014;90(1):S30.
   Google Scholar
• Matthiesen C, Thompson JS, De La Fuente Herman T, et al. Use of stereotactic body radiation therapy for medically inoperable multiple primary lung cancer. J Med Imaging Radiat Oncol. 2012;56(5):561–566.
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Hammerman SF, Kavanagh BD, et al. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48(4):578–583.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–1565.
   PubMed Web of Science ®Google Scholar
• Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, PACIFIC Investigators, et al. overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar